Brief: Nls Pharmaceutics AG Announces Positive Interim Top-Line Data For Quilience (Mazindol Er) In Patients With Narcolepsy
16/03/2022 11:37
March 16 (Reuters) - NLS Pharmaceutics AG NLSP.O :
* NLS PHARMACEUTICS AG - ANNOUNCES POSITIVE INTERIM TOP-LINE
DATA
FOR QUILIENCE (MAZINDOL ER) IN PATIENTS WITH NARCOLEPSY
* NLS PHARMACEUTICS AG - SAFETY AND TOLERABILITY DATA
CONSISTENT
WITH PRIOR MAZINDOL CLINICAL TRIALS, NO REPORTED SAES
Further company coverage: NLSP.O
Recent news on NewcelX AG
See all newsBrief: Newcelx Announces Pricing Of $1.4 Million Equity Financing At 20% Premium Pricing
Brief: Newcelx Submits Pre-IND Package To FDA For NCEL-101 For Treatment Of Type 1 Diabetes
Brief: Newcelx Updates Corporate Presentation To Highlight Type 1 Diabetes Flagship Program
U.S. STOCKS ON THE MOVE-Eli Lilly, Space stocks, Anixa Biosciences
U.S. STOCKS ON THE MOVE-Intel, Tempus AI, Boeing